Article
Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil.
Drug design, development and therapy - 1 Jan 2020
Ortner Marion, Stange Marion, Schneider Heike, Schröder Charlotte, Buerger Katharina, Müller Claudia, Müller-Sarnowski Felix, Diehl-Schmid Janine, Förstl Hans, Grimmer Timo, Steimer Werner
Abstract excerpt
BACKGROUND: The efficacy of acetylcholinesterase inhibitors (AChE-I) might depend on blood concentration. While rivastigmine metabolism is independent of the cytochrome P450 system, its isoenzymes, especially CYP2D6, metabolize donepezil. CYP2D6 polymorphisms can cause altered enzyme activity resulting in lower or higher than expected drug concentrations of donepezil. OBJECTIVE: We investigated correlations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.